Background. Diabetic macular edema (DME) is a major cause of vision loss in diabetics that
is currently mainly treated by antivascular endothelial growth factor (VEGF) agents. The …

Background: Diabetic macular edema (DME) is a major cause of vision loss in diabetics
worldwide. Anti-vascular endothelial growth factor (anti-VEGF) agents have become the …

Objective. To evaluate macular perfusion changes following intravitreal bevacizumab
injections for diabetic macular edema (DME) using spectral domain optical coherence …

Objective To quantify changes in optical coherence tomography angiography (OCTA)
parameters following intravitreal anti–vascular endothelial growth factor treatment for …

Purpose To report a case of adult-onset Coats' disease that had worsening of macular
edema and progressive macular traction following cryotherapy and repeated intravitreal …

The objective of this study was to determine the correlation between topographic vessel
density (VD) and retinal thickness (RT) reductions induced by vascular endothelial growth …

Diabetic macular edema (DME) is a vision-threatening complication of diabetic retinopathy
and causes significant morbidity in patients. Anti-vascular endothelial growth factor (VEGF) …

Purpose: To evaluate the use of intravitreal bevacizumab injections for the treatment of
intraretinal cystic spaces associated with gyrate atrophy of the choroid and retina. Methods …

Background To evaluate changes in central macular thickness (CMT), subfoveal choroidal
thickness (SFCT), and foveal vessel density (VD) in deep and superficial capillary plexuses …

Background This study was done to evaluate macular perfusion changes following
intravitreal bevacizumab injections for diabetic macular edema (DME) using spectral domain …